United States
Synbio Technologies, established in 2013, is a pioneering company in the fields of Biotechnology, Health Care, and Pharmaceutical. Headquartered in the United States, the company is built on the vision of "Changing the world, one sequence at a time."
With a comprehensive suite of synthetic biology services, Synbio Technologies has honed its capabilities in DNA sequencing, writing, and editing. Their offerings extend across crucial applications such as diagnostic DNA probes, precision medicine, protein production, and vaccine development. By leveraging advanced bioinformatics and proprietary algorithms, they enhance processes like antibody discovery, which includes specialized services such as hybridoma sequencing and affinity maturation.
This strategic focus positions Synbio Technologies as a trusted partner in the scientific community. Despite lacking recent investment activity, the company's robust technological platform highlights its significant potential for future growth and industry impact. Investors might find value in the scalability and innovation of Synbio Technologies as it contributes to the evolving landscape of synthetic biology.
DNA Script
